滤泡性淋巴瘤的生物学作为脆弱性:遗传学、表观遗传学与免疫遗传学
滤泡性淋巴瘤(FL)是最常见的惰性非霍奇金淋巴瘤,以复发和转化风险为特征。高通量测序、空间转录组和影像技术揭示了其遗传、表观遗传和免疫遗传学特征及治疗脆弱性。除t(14;18)累及BCL2外,染色质和组蛋白修饰相关基因的额外突变驱动前驱细胞持续与演化,肿瘤微环境促进免疫逃逸;BCL2抑制剂、表观遗传调节剂和免疫治疗等靶向治疗由此出现。
要点
- FL除t(14;18)累及BCL2外,还需染色质和组蛋白修饰相关基因的额外致癌突变。
- 肿瘤微环境中的T细胞、基质细胞和巨噬细胞促进肿瘤免疫逃逸并影响预后。
- 靶向治疗包括BCL2抑制剂、表观遗传调节剂和免疫治疗;早期靶向治疗而非当前「观察等待」对改善结局至关重要。
核心结论
- FL的遗传、表观遗传和免疫遗传学特征揭示其生物学与潜在治疗脆弱性。
- 治愈FL需要选择性清除癌症前驱细胞且对正常细胞影响最小的靶向治疗,以预防复发并避免有害副作用。
- 根除微小残留病应作为主要目标,而非等待临床复发。
- 未来研究须优先开发准确的实验模型、阐明FL前驱细胞并深入理解其异质性、依赖性、进展和转化机制。
- 在FL早期阶段实施靶向治疗而非当前「观察等待」方法,对改善患者结局至关重要。
研究设计与样本
- 综述,总结高通量测序、空间转录组学和影像技术揭示的FL遗传、表观遗传和免疫遗传学特征。
主要发现
- FL是最常见的惰性非霍奇金淋巴瘤,以复发病程和转化为侵袭性弥漫性大B细胞淋巴瘤的风险为特征。
- FL主要由累及BCL2的t(14;18)易位驱动,但发病还需额外致癌突变,尤其是染色质和组蛋白修饰调节基因。
- 早期遗传和表观遗传改变促进癌症前驱细胞的持续和演化,为淋巴瘤发生奠定基础。
- 肿瘤微环境对FL进展和患者预后至关重要,T细胞、基质细胞和巨噬细胞在促进肿瘤免疫逃逸中起关键作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Follicular lymphoma (FL) represents a heterogeneous group of B-cell neoplasms with distinct genetic, epigenetic, microenvironmental, and clinical features. It is the most prevalent indolent non-Hodgkin lymphoma, characterized by a relapsing course and risk of transformation to aggressive diffuse large B-cell lymphoma. Recent advances in high-throughput sequencing, spatial transcriptomics, and imaging technologies uncovered genetic, epigenetic, and immunogenetic features underpinning FL, offering insights into its biology and potential therapeutic vulnerabilities. Although FL is primarily driven by the hallmark t(14;18) translocation involving BCL2, its pathogenesis requires additional oncogenic mutations, particularly in genes regulating chromatin and histone modifications. These early genetic and epigenetic alterations promote the persistence and evolution of cancer precursor cells, setting the stage for lymphomagenesis. The tumor microenvironment is also crucial in FL progression and patient prognosis, with T cells, stromal cells, and macrophages playing pivotal roles in facilitating tumor immune escape. Targeted therapies, including B-cell lymphoma 2 (BCL2) inhibitors, epigenetic modulators, and immunotherapies, have emerged from this deeper understanding of FL biology. Achieving a cure for FL will require targeted therapies that selectively eliminate cancer precursor cells with minimal impact on normal cells, thus preventing relapse and avoiding harmful side effects. Eradicating minimal residual disease should be a primary objective rather than waiting for clinical relapse. Future research must prioritize the development of accurate experimental models, the elucidation of FL precursors, and a deeper understanding of its heterogeneity, dependencies, progression, and mechanisms driving transformation. Implementing targeted therapies at FL early stages, instead of the current "watch and wait" approach, will be essential to improve patient outcomes.
引用
- Araujo-Ayala F, Béguelin W. Biology as vulnerability in follicular lymphoma: genetics, epigenetics, and immunogenetics. Blood. 2025. PMID: 40089999. doi:10.1182/blood.2024026020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。